Cargando…

Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome

BACKGROUND: Polycystic ovary syndrome (PCOS) causes anovulation and is associated with a reduced clinical pregnancy rate. Metformin, which is widely used for treating PCOS, can lead to successful pregnancy by restoring the ovulation cycle and possibly improving endometrial abnormality during the imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohara, Miki, Yoshida-Komiya, Hiromi, Ono-Okutsu, Miho, Yamaguchi-Ito, Akiko, Takahashi, Toshifumi, Fujimori, Keiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165781/
https://www.ncbi.nlm.nih.gov/pubmed/34053455
http://dx.doi.org/10.1186/s12958-021-00765-6
_version_ 1783701382120865792
author Ohara, Miki
Yoshida-Komiya, Hiromi
Ono-Okutsu, Miho
Yamaguchi-Ito, Akiko
Takahashi, Toshifumi
Fujimori, Keiya
author_facet Ohara, Miki
Yoshida-Komiya, Hiromi
Ono-Okutsu, Miho
Yamaguchi-Ito, Akiko
Takahashi, Toshifumi
Fujimori, Keiya
author_sort Ohara, Miki
collection PubMed
description BACKGROUND: Polycystic ovary syndrome (PCOS) causes anovulation and is associated with a reduced clinical pregnancy rate. Metformin, which is widely used for treating PCOS, can lead to successful pregnancy by restoring the ovulation cycle and possibly improving endometrial abnormality during the implantation period. However, the mechanism by which metformin improves endometrial abnormality remains unknown. Women with PCOS have an aberrant expression of steroid hormone receptors and homeobox A10 (HOXA10), which is essential for embryo implantation in the endometrium. METHODS: In this study, we examined whether metformin affects androgen receptor (AR) and HOXA10 expression in PCOS endometrium in vivo and in human endometrial cell lines in vitro. Expression of AR and HOXA10 was evaluated by immunohistochemistry, fluorescent immunocytochemistry, and western blot analysis. RESULTS: AR expression was localized in both epithelial and stromal cells; however, HOXA10 expression was limited to only stromal cells in this study. In women with PCOS, 3 months after metformin treatment, the expression of AR was reduced in epithelial and stromal cells in comparison to their levels before treatment. In contrast, HOXA10 expression in the stromal cells with metformin treatment increased in comparison to its level before treatment. Further, we showed that metformin counteracted the testosterone-induced AR expression in both Ishikawa cells and human endometrial stromal cells (HESCs); whereas, metformin partly restored the testosterone-reduced HOXA10 expression in HESCs in vitro. CONCLUSIONS: Our results suggest that metformin may have a direct effect on the abnormal endometrial environment of androgen excess in women with PCOS. TRIAL REGISTRATION: The study was approved by the Ethical Committee of Fukushima Medical University (approval no. 504, approval date. July 6, 2006), and written informed consent was obtained from all patients. https://www.fmu.ac.jp/univ/sangaku/rinri.html
format Online
Article
Text
id pubmed-8165781
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81657812021-06-01 Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome Ohara, Miki Yoshida-Komiya, Hiromi Ono-Okutsu, Miho Yamaguchi-Ito, Akiko Takahashi, Toshifumi Fujimori, Keiya Reprod Biol Endocrinol Research BACKGROUND: Polycystic ovary syndrome (PCOS) causes anovulation and is associated with a reduced clinical pregnancy rate. Metformin, which is widely used for treating PCOS, can lead to successful pregnancy by restoring the ovulation cycle and possibly improving endometrial abnormality during the implantation period. However, the mechanism by which metformin improves endometrial abnormality remains unknown. Women with PCOS have an aberrant expression of steroid hormone receptors and homeobox A10 (HOXA10), which is essential for embryo implantation in the endometrium. METHODS: In this study, we examined whether metformin affects androgen receptor (AR) and HOXA10 expression in PCOS endometrium in vivo and in human endometrial cell lines in vitro. Expression of AR and HOXA10 was evaluated by immunohistochemistry, fluorescent immunocytochemistry, and western blot analysis. RESULTS: AR expression was localized in both epithelial and stromal cells; however, HOXA10 expression was limited to only stromal cells in this study. In women with PCOS, 3 months after metformin treatment, the expression of AR was reduced in epithelial and stromal cells in comparison to their levels before treatment. In contrast, HOXA10 expression in the stromal cells with metformin treatment increased in comparison to its level before treatment. Further, we showed that metformin counteracted the testosterone-induced AR expression in both Ishikawa cells and human endometrial stromal cells (HESCs); whereas, metformin partly restored the testosterone-reduced HOXA10 expression in HESCs in vitro. CONCLUSIONS: Our results suggest that metformin may have a direct effect on the abnormal endometrial environment of androgen excess in women with PCOS. TRIAL REGISTRATION: The study was approved by the Ethical Committee of Fukushima Medical University (approval no. 504, approval date. July 6, 2006), and written informed consent was obtained from all patients. https://www.fmu.ac.jp/univ/sangaku/rinri.html BioMed Central 2021-05-31 /pmc/articles/PMC8165781/ /pubmed/34053455 http://dx.doi.org/10.1186/s12958-021-00765-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ohara, Miki
Yoshida-Komiya, Hiromi
Ono-Okutsu, Miho
Yamaguchi-Ito, Akiko
Takahashi, Toshifumi
Fujimori, Keiya
Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome
title Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome
title_full Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome
title_fullStr Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome
title_full_unstemmed Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome
title_short Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome
title_sort metformin reduces androgen receptor and upregulates homeobox a10 expression in uterine endometrium in women with polycystic ovary syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165781/
https://www.ncbi.nlm.nih.gov/pubmed/34053455
http://dx.doi.org/10.1186/s12958-021-00765-6
work_keys_str_mv AT oharamiki metforminreducesandrogenreceptorandupregulateshomeoboxa10expressioninuterineendometriuminwomenwithpolycysticovarysyndrome
AT yoshidakomiyahiromi metforminreducesandrogenreceptorandupregulateshomeoboxa10expressioninuterineendometriuminwomenwithpolycysticovarysyndrome
AT onookutsumiho metforminreducesandrogenreceptorandupregulateshomeoboxa10expressioninuterineendometriuminwomenwithpolycysticovarysyndrome
AT yamaguchiitoakiko metforminreducesandrogenreceptorandupregulateshomeoboxa10expressioninuterineendometriuminwomenwithpolycysticovarysyndrome
AT takahashitoshifumi metforminreducesandrogenreceptorandupregulateshomeoboxa10expressioninuterineendometriuminwomenwithpolycysticovarysyndrome
AT fujimorikeiya metforminreducesandrogenreceptorandupregulateshomeoboxa10expressioninuterineendometriuminwomenwithpolycysticovarysyndrome